Seminal
The magazine and atlas of EU-funded researchA new publication from the web and AI team at Scott Charnley

Atlas / Greece

Research and Innovation Action · Running

AI-PROGNOSIS Artificial intelligence-based Parkinson’s disease risk assessment and prognosis

Coordinator
Aristotelio Panepistimio Thessalonikis, Greece
Runs
1 July 2023 to 30 June 2027
Status
Running
EU funding
€5.3m
Total cost
€5.5m
Partners
19 organisations in 11 countries
Type
Research and Innovation Action
Grant agreement
101080581

What the project is doing

In the project's own words, from its summary on CORDIS.

Parkinson’s disease (PD) is the most common neurodegenerative movement disorder, with a multifactorial aetiology, heterogeneous manifestation of motor and non-motor symptoms, and no cure. PD is often missed or misdiagnosed, as early symptoms are subtle and common with other diseases, allowing for considerable damage to occur before treatment. Moreover, selecting the optimal medication regimen is usually a lengthy, “trial and error” process, leading to critical, costly non-adherence.

Following a trustworthy and inclusive approach to AI development and based on multidisciplinary expertise and broad stakeholder engagement, AI-PROGNOSIS aims to advance PD diagnosis and care by: 1) developing novel, predictive AI models for personalised PD risk assessment and prognosis (in terms of time to higher disability transition and response to medication) based on multi-source patient records and databases, including in-depth health, phenotypic and genetic data, 2) implementing a system of biomarkers informing the AI models by tracking key risk/progression markers in daily living, and ultimately 3) translating the models and digital biomarkers into a validated, privacy-aware AI-driven toolkit, supporting healthcare professionals (HCPs) in disease screening, monitoring and treatment optimization via quantitative, explainable evidence, and empowering individuals with/without PD with tailored insights for informed health management.

Who is involved

OrganisationCityCountryRole
Aristotelio Panepistimio ThessalonikisThessalonikiGreeceCoordinator
Ainigma TechnologiesLeuvenBelgiumParticipant
Katholieke Universiteit LeuvenLeuvenBelgiumParticipant
SquaredevBruxelles / BrusselBelgiumParticipant
Kypriako Idryma Erevnon Gia Ti Myiki DistrofiaAgios DometiosCyprusParticipant
Abbvie Deutschland GmbH & Co KgWiesbadenGermanyParticipant
Neurotransdata GmbHNeuburg An Der DonauGermanyParticipant
Technische Universitaet DresdenDresdenGermanyParticipant
Diadikasia Business Consulting Symvouloi Epicheiriseon AeAthinaGreeceParticipant
Ethniko Kentro Erevnas Kai Technologikis AnaptyxisThermi ThessalonikiGreeceParticipant
Fundacion Iniciativa Para Las Neurosciencias - Foundation for Initiatives in NeuroscienceMadridSpainParticipant
Centre Hospitalier Universitaire De ToulouseToulouse Cedex 3FranceParticipant
Netcompany S.a.LuxembourgLuxembourgParticipant
Smartsol SiaRigaLatviaParticipant
Faculdade De Motricidade HumanaCruz Quebrada LisboaPortugalParticipant
Uppsala UniversitetUppsalaSwedenParticipant
King's College LondonLondonUnited KingdomAssociatedpartner
Queen Mary University of LondonLondonUnited KingdomAssociatedpartner
The Chancellor, Masters and Scholars of the University of OxfordOxfordUnited KingdomAssociatedpartner

Source: CORDIS, European Commission. Data of 5 Nov 2026, reused under the Commission's reuse policy. View on CORDIS · Grant DOI